Mesentech is firstly concentrating product development on its lead product C3 in clinical conditions that offer “fast” market entry.
We are progressing C3 for the treatment of the Orphan Disease, osteogenesis imperfecta (also called Brittle Bone Disease). There is no cure for this disease and treatment options include surgical insertion of rods into the bones, or treatment with bisphosphonate drugs to block resorption of bone and maintain bone mass. C3 would be the first product available that can grow new strong bone. Orphan Diseases allow for faster clinical development and regulatory processes.
Brittle Bone Disease is analogous to osteoporosis (often called Brittle Bone Disease of the elderly). Mesentech plans to use the clinical data obtained for C3 in treating osteogenesis imperfecta to seek a commercial partner for its development in the much larger market of osteoporosis.
Mesentech is also progressing a single dose topical formulation of C3 for bone regeneration to support dental implant placement. This is a large commercial market with lower barriers to entry and pricing and where there are no bone regeneration products currently available.
Mesentech plans to use the clinical data obtained for C3 in dental implant placement to seek a commercial partner for its development in the analogous indication of spinal fusion, where the current market option has significant side-effects.